Search

Search Constraints

You searched for: Author/Creator Fort, Madeline

Search Results

1. 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells. (9th November 2020)

2. 718 AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells. (9th November 2020)

4. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms – Report of an international collaborative study. Issue 4 (December 2020)

6. Unexpected Thrombocytopenia and Anemia in Cynomolgus Monkeys Induced by a Therapeutic Human Monoclonal Antibody. (October 2013)